Today's Review on Biotech Equities - Kite Pharma, Organovo Holdings, BioMarin Pharma, NephroGenex, and Neuralstem

LONDON, January 9, 2015 /PRNewswire/ --

Investor-Edge has initiated coverage on the following equities: Kite Pharma Inc. (NASDAQ: KITE), Organovo Holdings Inc. (NYSE MKT: ONVO), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), NephroGenex Inc. (NASDAQ: NRX), and Neuralstem Inc. (NYSE MKT: CUR). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets surged on Thursday, January 08, 2015, as the Dow Jones Industrial Average finished at 17,907.87, up 1.84% and the NASDAQ Composite closed at 4,736.19, up 1.84%. The S&P 500 finished the session 1.79% higher at 2,062.14. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 819.86, up 1.72%, with the index gaining 11.71% in the previous three months. Register for your complimentary reports on these five stocks at:  

http://investor-edge.com/register

Kite Pharma Inc.'s stock edged 0.08% higher, to close the day at $71.03. The stock recorded a trading volume of 1.00 million shares, above its three months average volume of 0.72 million shares. The company's shares oscillated between $68.61 and $71.90 during the session. Over the last three trading sessions and over the past one month, Kite Pharma Inc.'s shares have gained 1.84% and 37.52%, respectively. Further, the stock has rallied 112.66% in the previous three months. The company is trading above its 50-day moving average of $48.14. Additionally, Kite Pharma Inc.'s stock has a Relative Strength Index (RSI) of 83.99. Sign up and read the free notes on KITE at:

http://get.Investor-Edge.com/pdf/?c=Kite%20Pharma&d=09-Jan-2015&s=KITE

On Thursday, shares in Organovo Holdings Inc. recorded a trading volume of 0.80 million shares, lower than its three months average volume of 1.09 million shares. The stock ended the day at $6.91, which was 0.44% above its previous day's closing of $6.88, and registered an intraday range of $6.80 and $7.10. Organovo Holdings Inc.'s shares have fallen by 2.26% in the previous three trading sessions, while the stock has gained 18.32% in the last one month and 15.17% in the previous three months. The company is trading above its 50-day moving average of $6.61, while the 50-day moving average is below the 200-day moving average of $6.99.  Furthermore, shares of Organovo Holdings Inc. have an RSI of 51.94. The complimentary notes on ONVO can be downloaded as in PDF format at:

http://get.Investor-Edge.com/pdf/?c=Organovo%20Holdings&d=09-Jan-2015&s=ONVO

BioMarin Pharmaceutical Inc.'s stock advanced 0.45% higher to end Thursday's session at $94.18, hitting a new 52-week high of $97.93. The stock recorded a trading volume of 1.18 million shares, which at par with the three months average volume. The company's shares fluctuated between $93.27 and $97.93 during the session. BioMarin Pharmaceutical Inc.'s shares have surged 34.20% in the past one year. Further, the stock has gained 1.15% in the previous three trading sessions and 30.95% over the last three months. The company is trading above its 50-day and 200-day moving averages. BioMarin Pharmaceutical Inc.'s 50-day moving average of $88.32 is above its 200-day moving average of $70.36. Additionally, the stock has an RSI of 58.13. Register for free on Investor-Edge and access the latest research on BMRN at:

http://get.Investor-Edge.com/pdf/?c=BioMarin%20Pharma&d=09-Jan-2015&s=BMRN

On Thursday, shares in NephroGenex Inc. fluctuated between $9.21 and $11.00 before ending the session 2.93% higher at $9.48. The stock reported a trading volume of 0.96 million shares, higher than its three months average volume of 0.47 million shares. Although NephroGenex Inc.'s stock has lost 6.60% in the previous three trading sessions, it has rallied 93.47% in the last one month and 117.43% over the past three months. The company is trading above its 50-day and 200-day moving averages of $5.22 and $5.41, respectively. Moreover, shares of NephroGenex Inc. have an RSI of 64.59. The complete research on NRX is available for free at:

http://get.Investor-Edge.com/pdf/?c=NephroGenex&d=09-Jan-2015&s=NRX

Neuralstem Inc.'s stock finished Thursday's session 2.51% lower at $3.50. A total of 1.52 million shares were traded, which was much above its three months average volume of 0.69 million shares. The stock vacillated between $3.40 and $3.62 during the session. Over the previous three trading sessions and over the last one month, Neuralstem Inc.'s shares have surged 17.45% and 21.95%, respectively. Additionally, over the past three months, the stock has gained 14.75%. The company's shares are trading above their 50-day and 200-day moving averages. Moreover, the stock's 200-day moving average of $3.43 is greater than its 50-day moving average of $2.80. Neuralstem Inc.'s stock has an RSI of 68.37. Free in depth research on CUR is available at:

http://get.Investor-Edge.com/pdf/?c=Neuralstem&d=09-Jan-2015&s=CUR

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED